Just a few weeks after Novartis announced it’s taken an ownership stake in Colorado’s SomaLogic, the proteomics company has raised $16.5 million, according to a regulatory filing.
Although SomaLogic’s keeping quiet on who’s invested and what it’s for, the company’s an early player in applying proteomics to the diagnostics field – and Novartis has a demonstrated interest in the field. The Swiss pharma giant has its own Center for Proteomic Chemistry, after all, and is building up a catalogue of proteomic compounds that can be eventually translated into new medications.
SomaLogic, in addition to diagnostics, does just that. Its SOMAmer reagent library, for instance, measures more than a thousand proteins, including kinases, cytokines, growth factors, protease inhibitors and hormones.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
SomaLogic has outlined its proteomics applications in a number of spaces:
Though the privately held SomaLogic has been around more than a decade, it’s raised $46.5 million since 2010.
